U.S. Markets open in 3 hrs 20 mins

Compugen Ltd. (CGEN)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
3.65+0.15 (+4.29%)
At close: 4:00PM EDT
People also watch
CERSCRISCAMTCYTKARQL
  • C
    C
    C
    Perplexed by conference calls? Have you ever wondered why some of you who have waited patiently to pose a question, only to find that your call was not taken, followed by a gal saying that there were no further questions?
    Consider this response that I received from Elana Holtzman.She's the new IR person,who replaced Susanna:
    "I would like to point out that it is common practice to allow primarily the sell side to ask questions on conference calls as opposed to shareholders (institutional or private) and that there is no obligation to allow all participants to ask questions during these calls. In addition, engaging the sell side is an important component in our efforts to broadening our shareholder base to include more institutional shareholders. In the long run, that should have a positive impact on liquidity and share performance which is in the best interest of existing shareholders."
  • E
    Ed
    Ed
    Roughly a 30% move and this board is DEAD. We were told over and over that by EOY a deal. Sort of feel confident that we are about to hear something good with the SP action lately.

    Cheers.
  • s
    sbh3117
    sbh3117

    Hi everybody,

    I'm not sure everybody saw this but Merck is acquiring Rigontec, a small life science company in the immune-oncology sector with one phase I drug that employs a novel mAb pathway. A relevant comp for Compugen shareholders, IMO. Here are the details:

    http://www.genengnews.com/gen-news-highlights/merck-to-acquire-rigontec-expanding-cancer-immunotherapy-franchise/81254891

    sbh

    Merck to Acquire Rigontec, Expanding Cancer Immunotherapy Franchise | GEN
    Keytruda® developer Merck & Co. to add Rigontec's technology targeting the retinoic acid-inducible gene I (RIG-I) pathway to induce both immediate and long-term antitumor immunity
    www.genengnews.com
  • S
    SJS
    SJS
    Well seems like we got what some of you desperately wanted. Anat, Ari and Zurit all invested in the company. When you consider that Anat owns about 2% of the company she already has plenty of incentive to drive up the stock the noise some of you make is often ridiculousness. Of course that is my opinion.

    Martin is leaving and Paul got himself quite a deal, but if we are going to move this forward that is the cost. We will know soon enough if he is worth it. But 500k options at $2.85 pretty darn good. Before we hear more complaining that's the price unless of course you want the type of candidate that many of you pushed for several months ago.
  • A
    Anonymous
    Anonymous
    venomous posts: there is a growing amount of middle school like talk on this site. I appreciate everyone's frustration that I share but the tone and attitude while entertaining is unwarranted. sell your stock and move on or appreciate the risks of this long-term scientific/business endeavor. I am a strong believer in Anat and the scientific team.They are advancing the science which is the key to growing the value of the company. I view the market cap as an anomaly that will be corrected once we move a very little further on the science. that said, there are risks and if you want less risk find a fund or another stock but enough of the personal attacks against Anat and others. It's just mean spirited and not who we ought to be as adults. And I am saying this as someone who has lost on paper over a million dollars if I had sold when the stock was at 13. Hang in or move on!
  • P
    Patrick S
    Patrick S
    why did this stock pop yesterday?
  • J
    J. Swift
    J. Swift
    Down 10% after the bell today. What's going on?
  • n
    neal
    neal
    Our glorious and esteemed ceo, deserves nothing. In that nothing has been accomplished. Other than, what wasnt known, is now known.
  • n
    neal
    neal
    You have it backwards, No CEO is going to move this stock. The only thing that will, is proven science.
  • D
    Doug
    Doug
    The Company is not a sham. The Company is a shame.

    Why did most of us get involved with Compugen (a relationship that is increasingly resembling an abusive marriage)?

    Because we were led to believe that the company had figured out a highly innovative, groundbreaking way to identify potential drug candidates, and that those potential candidates themselves would be of immense interest to the larger pharma industry.

    That belief has not been misplaced, as the recent Moonshot patent awarded to 701 well illustrates.

    However, there is more to the story of our widespread conviction in the company. And that is the ability of the company to take this science and to make a profitable company out of it.

    After all, we were invited to buy shares in a for profit, publicly traded business, not to extend a research grant, nor to make a charitable contribution to a foundation.

    Here we had reason to believe that the former CEO, then co-CEO and then only the Chairman, Martin Gerstel, would be instrumental in helping us to accomplish this critical second part of the bargain. After all, Martin had parlayed a perennially rocky ride at Alza into a more than $10billion exit, some 20+ years ago. That was, and continues to be real money.

    But it hasn’t worked out that way. Martin is leaving, hardly in a blaze of glory. One senses he was marginalized, if not outright pushed out. What does that leave? Where is the cavalry riding in to make us all rich and famous?

    Anat is undoubtedly a gifted scientist, but she has not shown herself to be a leader of a public company, inspiring confidence, providing clarity, and above all, grabbing the brass ring of doing deals.

    The company has gathered scientific advisers, has made significant progress in identifying and advancing potential targets, but since the Bayer deal of more than four years ago, has nothing to show for it commercially.

    Under pressure from the great unwashed – us, the shareholders – the company said that they were committed to at least one commercialization in 2017. This has made 2017 a put up or shut up year for us all.

    The year is not over, but the stirrings from management have – surprise! – not inspired much confidence as to the putting up part of the challenge. If anything, lawyers have descended, only exacerbating the instincts of management to be mum.

    No, we don’t have a sham. We have a company that needs more savvy, business oriented, market oriented, SUCCESS oriented management.

    We have no choice to root for the team that is in place now. But, if the upshot of 2017 is continued failure, we would be fools not to demand a new team to deliver on the real potential of what we invested in.
  • B
    BANKI
    BANKI
    patience pays off
    Look what "Kite Parma" did today
  • W
    Wkre
    Wkre
    The market is closed in Israel on Friday and it looks like the stock is actually going to go up for a change. It would be great if the Israelis would stop mutilating their own company.
  • A
    Anonymous
    Anonymous

    Rursus detestatus sum disciplinam minutatim et dixi: http://dataunion.tistory.com/10399

    Compugen Ltd. NASDAQ : CGEN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.3 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • s
    sbh3117
    sbh3117
    Given the understandable stockholder pessimism as a result of the long, painful wait for commercial news and the concerns about adequate cash, I just wanted to remind investors of the importance of the Moonshot patent for COM-701. From Compugen’s press release:

    “The patent was issued under the USPTO’s pilot program providing early review for patent applications pertaining to cancer immunotherapy in support of the White House Cancer Moonshot program, and is one of less than a dozen patents granted under the program to date.”

    The issuance of this patent provides substantive external validation of the potential value of COM-701, and when Compugen decides to license out this monoclonal antibody, Big Pharma will certainly take notice. Given the text and subtext of the most recent conference call, Bayer is certainly interested, and I would be surprised, as a result of this external validation, if other Big Pharma companies were not interested as well.

    Furthermore, as other board members have noted, when COM-701 is licensed out (IMO, within the next 9 months), the upfront will likely be significantly higher than the current market cap of the company, approximately $150 million. Thus, a deal will likely provide cash for the next 3 years or longer.

    In sum, the Moonshot patent was very important news for the company, and I hope this external validation will provide comfort to those long-term shareholders who have managed to stay invested as we wait for the next commercial announcement.

    sbh
  • A
    AJH
    AJH
    What many of us investors would like to see from the company in terms of ongoing PR would be notes translating the science into lay terms with business implications. And this would help go a long way in re-establishing investor confidence in the company.

    For example, it would be very helpful to understand that the patent on 701 – was awarded pursuant to the Moon Shots Program. But what does this mean and what is its commercial significance?

    Most abstruse scientific presentations by the company are largely wasted… they pass over its investors like water off a duck’s back. My understand is v. simple: we’re looking at a first-in-class candidate involving a novel pathway that must be addressed in order to treat certain forms of cancer, either by itself or in combination. This is massive and groundbreaking and should not be mixed in a soup of material that is unfathomable to most investors.
    And the value of 701?
    Are Bayer specifically negotiating a deal around this candidate? We don't know. But we do know from both CGEN and Bayer that they are in serious discussions about broadening their immuno-oncology collaboration.
    And of course neither company would acknowledge this fact were not their discussions at a very advanced state.

    Now, let’s be logical, Bayer can’t be the only company interested in such a key, groundbreaking discovery.
    So my conclusion is: $3 for this share is ludicrous, but the price has been and will be a function of the company’s incomprehensibly obtuse public & investor relations, and so it will remain until the next commercial announcement.
  • B
    BANKI
    BANKI
    Are all analysts wrong when valuing the share at $ 14 and actually it trades less than $ 3?
    Is this a purchase opportunity that will not come back?
  • n
    neal
    neal
    sorry. If the proteins had value, this would be a 5-10 billion dollar company, as of today they have not been proven as such.
  • n
    neal
    neal
    Phase one trial worth 1 bil. cap, phase 2 4 bil. cap phase 3 8 bil cap drug= 25 bil- 75 bil cap. That is the wager you are buying for the 3 lottery ticket.
  • A
    AJH
    AJH
    We are currently looking at an insane situation where the combined upfront for 701 and 902 could exceed twice the current market cap. Needless to say, this does not take into account the prospects for 15001 and 15001T and the myloid candidates. Is this the time to sell the company to Bayer? Thoughts, anyone.
  • n
    neal
    neal
    Nothing to do with management. Either the mworks or it doesnt. Ill make it plain and simple, if the proteins had value this would b